Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
· Strong revenue generation in Q4 2023, including SEK 43m in Idefirix[®] product sales supported by growth in new markets such as U.K., Germany, and Spain · Encouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosing · Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMDLund, January 6, 2024. Hansa Biopharma today announced a business update for the fourth quarter of 2023 and certain preliminary, unaudited key financials for the fourth quarter and full year 2023. Søren Tulstrup,